Abstract:Schistosoma mansoni infection leads to chronic schistosomiasis and severe hepatic fibrosis. We designed a liver-targeted lipid nanoparticle (LNP) carrying siRNA against type I TGF-β receptor (TGFβRI) mRNA to treat schistosomiasis-induced liver fibrosis in BALB/c mice. Knockdown of TGFβRI by LNP-siTGFβRI reduced LX-2 cell activation in vitro and alleviated liver fibrosis in S . mansoni -infected mice. αSMA and Col1a1 fibrotic markers in the liver tissues of infected mice were significantly suppressed in the treatment groups. In the serum of the LNP-siTGFβRI-treated groups, cytokines IFNγ, IL-1α, IL-6, IL-12, RANTES (CCL5), and TNFα increased, while GM-CSF, IL-2, IL-4, IL-10, IL-13, and KC (CXCL1) decreased compared to the control. Cell proportions were significantly altered in S . mansoni -infected mice, with increased CD56d NK cells and decreased CD19 + B cells and CD4 + T cells compared to naïve mice. Following LNP-siTGFβRI treatment, CD56d NK cells were downregulated, while B and memory Th cell populations were upregulated. The density of fibrotic regions significantly decreased with LNP-siTGFβRI treatment in a dose-dependent manner, and no systemic toxicity was observed in the major organs. This targeted siRNA delivery strategy effectively reduced granulomatous lesions in schistosomiasis-induced liver fibrosis without detectable side effects. This present study indicates that a liver-targeted lipid nanoparticles (LNPs) carrying siRNA against type I TGF-β receptor (TGFβRI) mRNA that we designed could be used to treat schistosomiasis-induced liver fibrosis. We demonstrated a liver-specific accumulation of LNPs upon intravenous injection in BALB/c mice at drug dose of 0.1 or 1 mg/kg twice a week for 4 weeks. In vitro and in vivo experiments both revealed reduced activation of HSC and alleviated liver fibrosis in S. mansoni-infected mice. The fibrotic markers αSMA and Col1a1 and serum cytokines including GM-CSF, IL-2, IL-4, IL-10, IL-13 and KC (CXCL1) from liver tissues were significantly suppressed in LNP-siTGFβRI treatment groups. FACS results indicated that following LNP-siTGFβRI treatment, CD56d NK cells showed downregulation, while B cell and memory Th cell populations were upregulated. Histological analysis showed the density of fibrotic regions were significantly decreased with LNP-siTGFβRI treatment in a dose-dependent manner and no systemic toxicity was observed in major organs. In this study, we provide a potentially targeted siRNA delivery strategy reducing granulomatous lesions for schistosomiasis-induced liver fibrosis treatment without detectable side effects. It is hoped that this study will provide effective new treatments for liver fibrosis caused by schistosomiasis in the future.

Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

IFN‐γ Gene Therapy by Intrasplenic Hepatocyte Transplantation: a Novel Strategy for Reversing Hepatic Fibrosis in Schistosoma Japonicum‐infected Mice

Hepatic stellate cell-targeted chemo-gene therapy for liver fibrosis using fluorinated peptide-lipid hybrid nanoparticles

Intrasplenic Transplantation of IL-18 Gene-Modified Hepatocytes: an Effective Approach to Reverse Hepatic Fibrosis in Schistosomiasis Through Induction of Dominant Th1 Response

Ppb Peptide-Mediated Sirna-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis.

MicroRNA 200a inhibits liver fibrosis of schistosoma

Single-cell RNA sequencing to dissect the immunological network of liver fibrosis in Schistosoma japonicum-infected mice

Pathology and molecular mechanisms of Schistosoma japonicum-associated liver fibrosis

HSC-targeted delivery of shRNA-TGFβ 1 by vitamin A-functionalized polyaminoglycoside for hepatic fibrosis therapy

Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease

MiR-130a-3p Alleviates Liver Fibrosis by Suppressing HSCs Activation and Skewing Macrophage to Ly6Clo Phenotype

Restoration of Sinusoid Fenestrae followed by Targeted Nanoassembly Delivery of an Anti‐Fibrotic Agent Improves Treatment Efficacy in Liver Fibrosis

Co-delivery of pirfenidone and siRNA in ZIF-based nanoparticles for dual inhibition of hepatic stellate cell activation in liver fibrotic therapy

A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III

Elaborately engineering of lipid nanoparticle for targeting delivery of siRNA and suppressing acute liver injury

Total flavonoids of litchi Seed alleviates schistosomiasis liver fibrosis in mice by suppressing hepatic stellate cells activation and modulating the gut microbiomes

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis

NLRP3 inflammasome inhibition decreases Schistosomiasis japonica-induced granulomatous inflammation and fibrosis in BALB/c mice

The egg ribonuclease SjCP1412 accelerates liver fibrosis caused by Schistosoma japonicum infection involving damage-associated molecular patterns (DAMPs)